首个脑机接口行业标准发布。 我国首个脑机接口行业标准发布 据央视新闻报道，国家药监局最新批准发布了《采用脑机接口技术的医疗器械 术语》医疗器械行业标 准。这是我国第一项脑机接口医疗器械标准，为脑机接口医疗器械产业高质量发展奠定基础。该标准将 于2026年1月1日正式实施，界定了采用脑机接口技术的医疗器械(简称脑机接口医疗器械)的术语和定 义。 作为前沿科技，近年来脑机接口的关注度持续提升。政策方面，今年8月，工业和信息化部、国家发展 改革委等七部门联合发布《关于推动脑机接口产业创新发展的实施意见》。 其中提出到2027年，我国脑机接口关键技术将取得突破，初步建立先进的技术体系、产业体系和标准体 系。脑机接口产品加快应用，产业规模不断壮大，打造2至3个产业发展集聚区，开拓一批新场景、新模 式、新业态。到2030年，脑机接口产业创新能力将显著提升，形成安全可靠的产业体系，构建具有国际 竞争力的产业生态，综合实力迈入世界前列。 多家公司脑机接口业务呈现新进展 据证券时报·数据宝统计，A股脑机接口概念股今年以来平均上涨62.55%，汉威科技、创新医疗、赛诺 医疗、荣泰健康的股价实现翻倍，涨幅均超170%。 7家公司9 ...

Core Insights - The domestic brain-computer interface (BCI) industry is entering a phase of accelerated development in 2025, with significant advancements emerging continuously [1] - Multiple A-share listed companies have disclosed recent updates on their BCI businesses, indicating a clear industry application blueprint and a push towards commercialization [2][5] Company Developments - MaiLand has focused on non-invasive BCIs, achieving technological accumulation in areas such as upper limb and hand movement robotics and non-invasive neural regulation, with clinical validation underway for key projects [2][7] - Xiangyu Medical has launched over 10 new products, including BCIs and exoskeleton robots, and has established a collaborative center for BCI rehabilitation treatment and neural regulation [3][7] - QiSheng Technology is exploring cross-industry integration with BCI technology, particularly in sleep health, and has set up a digital sleep industry fund [3] - Zhongke Information has established a laboratory for cognitive and smart medical applications, focusing on developing closed-loop BCI systems for intelligent anesthesia and rehabilitation [3][7] - Aipeng Medical is working on monitoring brain states during surgery and developing treatment systems for conditions like insomnia and ADHD [3][7] Industry Trends - The BCI industry is seeing a multi-faceted approach to commercialization, with companies accelerating investment and product rollout, supported by local policies that facilitate the commercialization process [5][6] - The Shanghai Medical Insurance Bureau has introduced new medical service pricing items for invasive and non-invasive BCI procedures, which is expected to clear obstacles for commercialization [6] - Companies like Daoshi Technology and Botuo Bio are making strategic investments in BCI-related ventures, indicating a growing interest in the sector [5][6]

人民财讯9月8日电，据翔宇医疗消息，公司"一种矩形波整形电路及电刺激设备"获发明专利，该专利的 核心技术创新是提供了一种能够削弱反向脉冲、输出接近纯净矩形波的电路，并满足高频输出正、负双 向矩形波的输出需求。 ...

Group 1: Xiangyu Medical - The brain-computer interface (BCI) shows clear prospects in rehabilitation, potentially shifting patients from "passive rehabilitation" to "active rehabilitation," reducing labor costs and improving outcomes [1] - The company has an integrated advantage with "BCI technology + proprietary rehabilitation equipment," having obtained registration for two EEG collection devices, with over 20 devices expected to be certified by year-end and nearly 100 by the end of next year [1] - More than 50 large hospitals are currently using the company's equipment, which is expected to contribute to performance in 2025 and significantly enhance performance in 2026 [1] - R&D investment has increased by 38.80% year-on-year, with 117 new patents added, totaling 1,933 patents, including several related to BCI technology [1] - The sales model starts with partnerships with top-tier hospitals to create benchmarks, gradually extending to grassroots levels and eventually entering the home market [1] Group 2: Fenghua Gaoke - In the first half of 2025, the company aims to achieve record highs in product sales and revenue through cost reduction, efficient innovation, and new market development [2] - Automotive electronics sales increased by 39% year-on-year, communications by 22%, industrial control by 21%, and sales to the top ten customers grew by 27% [2] - Supercapacitor sales surged by 138%, with breakthroughs in emerging markets such as computing power, energy storage, intelligent robotics, and low-altitude economy [2] - The company has launched new products including medium and high-voltage MLCCs, MI series alloy resistors, and S series automotive-grade thick film precision resistors, emphasizing high reliability, miniaturization, and high precision [2] - A pricing strategy based on market supply and demand has been implemented to optimize product structure and improve gross margins [2] - The company has initiated a successor plan for talent management and is attracting core technical teams [2] - A "1+2+4+4+N" strategy has been established to promote high-quality development through seven strategic initiatives and various special projects [2]

Group 1: Xiangyu Medical - The brain-computer interface (BCI) shows clear prospects in rehabilitation medicine, potentially shifting patients from "passive rehabilitation" to "active rehabilitation," thereby saving labor costs and improving outcomes [1] - The company possesses an integrated advantage of "BCI technology + proprietary rehabilitation equipment," having obtained registration certificates for two EEG collection devices, with over 20 devices expected to be certified by the end of the year and nearly 100 by the end of next year [1] - More than 50 large hospitals are currently using the company's equipment, which is expected to contribute to performance in 2025 and significantly enhance performance in 2026 [1] - R&D investment has increased by 38.80% year-on-year, with 117 new patents added, totaling 1,933 patents, including several related to BCI technology [1] - The sales model starts with partnerships with top-tier hospitals to create benchmarks, gradually extending to grassroots levels and eventually entering the home market [1] Group 2: Lingyi Technology - In the first half of 2025, the company achieved revenue of 23.625 billion yuan, a year-on-year increase of 23.35%, and a net profit of 930 million yuan, up 35.94% [2] - Revenue from the I-terminal business was 20.865 billion yuan, while the automotive and low-altitude economy business generated 1.183 billion yuan, and other businesses contributed 1.577 billion yuan [2] - The company holds core technologies in humanoid robotics, including servo motors and reducers, and has secured domestic and international orders, positioning itself as one of the top three manufacturers of embodied intelligent hardware globally [2] - In the AI server sector, the company is expanding into cooling and power supply businesses, with capabilities in CDU and liquid cooling modules, and has formed a joint venture with Bohua Xinda and Boke Electronics [2] - The company has repurchased shares worth 320 million yuan and plans to distribute a cash dividend of 139 million yuan, totaling 459 million yuan in returns to investors [2]

Core Insights - Xiangyu Medical hosted a brain-computer interface experience event in Lujiazui, Shanghai, showcasing 11 devices including lower limb exoskeleton robots and thought typing systems [1] Company Highlights - The event featured popular new products such as brain-computer interface lower limb exoskeleton robots, thought typing systems, intelligent care systems, and home-use microcurrent therapy devices [1]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Group 1 - The Shanghai Stock Exchange recently hosted the sixth Future Industry Salon themed "Brain-Computer Interface: Exploring the Digital Intelligence Era," attended by six listed companies and twelve companies from the brain-computer interface industry chain, along with twelve financial institutions [1] - Brain-computer interfaces (BCIs) create information channels between the brain and external devices, enabling direct information exchange, and are categorized into invasive and non-invasive technology routes [1] - The potential market space for BCIs is estimated to exceed 100 billion USD, with applications spanning healthcare, education, consumer products, and intelligent driving [1] Group 2 - In the healthcare sector, BCIs have already gained traction, supported by an integrated model of industry, academia, and research, with several Sci-Tech Innovation Board listed companies actively investing in the BCI field [1] - Xiangyu Medical has established a brain science laboratory and is collaborating with multiple universities and hospitals, having obtained registration certificates for two brainwave acquisition devices [2] - Youke Technology is providing intelligent computing support to Brain Tiger Technology to advance the application of BCI products in the treatment of patients with aphasia [2]

Core Insights - Xiangyu Medical has received national medical device registration certificates for its EEG machines, entering the clinical application phase, with expectations to obtain multiple Class II medical device registration certificates for "brain-machine interface" products in the second half of the year, promoting the transformation of related technological achievements [1] - The brain-machine interface market is projected to exceed 3.8 billion yuan by 2025 and reach 5.58 billion yuan by 2027, with a growth rate of 20% [1] - Xiangyu Medical initiated brain-machine interface research in 2017, relying on the Sun-BCILab brain science laboratory, and plans to further develop five platforms by 2024, creating a comprehensive rehabilitation ecosystem [1] - The company focuses on non-invasive brain-machine interface technology, integrating self-developed EEG collection devices, brain-controlled products, lifestyle products, and proprietary algorithms to enhance rehabilitation medical scenarios [1] - Xiangyu Medical collaborates with universities and hospitals to establish a closed-loop system of "research-clinical-transformation" [1] Industry Outlook - The chairman of Xiangyu Medical emphasized a "clinical demand-oriented" research logic, focusing on deep collaboration with clinical experts to ensure products address real clinical pain points [2] - The company aims to actively build a "brain-machine interface+" rehabilitation industry ecosystem, promoting the establishment of industry technical standards and clinical application norms to support high-quality development in the rehabilitation medical industry [2] Product Showcase - During the recent event in Shanghai, Xiangyu Medical showcased 11 devices, including brain-machine interface lower limb exoskeleton robots, brain-machine interface thought typing systems, and microcurrent therapy devices [4]

Group 1 - The medical device sector experienced a decline of 1.78% on September 2, with Jimin Health leading the losses [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable gainers in the medical device sector included Wende Biological, which rose by 7.61% to a closing price of 25.58, and Jinhao Medical, which increased by 6.66% to 29.48 [1] Group 2 - Jimin Health saw a significant drop of 10.02%, closing at 11.40, with a trading volume of 1.0859 million shares and a transaction value of 1.331 billion [2] - Other notable decliners included Rejing Biological, which fell by 8.72% to 186.79, and Yikang Haosheng, which decreased by 7.71% to 34.24 [2] - The medical device sector experienced a net outflow of 1.23 billion from major funds, while retail investors contributed a net inflow of 1.011 billion [2]